Local anesthesia with SleeperOne S4 computerized device vs traditional syringe and perceived pain in pediatric patients: a randomized clinical trial.

Local anesthesia is performed in dentistry before clinical procedures to avoid pain. Children can show fear at the sight of the needle and pain at its insertion. To make local anesthesia more comfortable, the use of computer-controlled local anesthetic delivery (CCLAD) systems has been developed to control the flow rate of the anesthetic solution injected through the needle. The aim of the present research is to evaluate and compare the discomfort felt by patients using a traditional syringe and the CCLAD system SleeperOne®, by considering pain, size sensation, bitterness, and vomit. 30 patients were included in the study and randomly assigned to traditional anesthesia or CCLAD. After injection, patients were assessed for the abovementioned outcomes. A Visual Analogue Scale (VAS) from 0 to 10 scores was used. As far as pain is concerned, statistically lower mean values were found in the Trial group (p < 0.05). Instead, concerning size, bitterness and vomit perceptions, no statistically significant differences were found between the groups (p > 0.05). Linear regressions were calculated considering technique, quadrant, dental arch, tooth, dentition, sex, and age as independent variables. The technique has shown to have a significant influence on pain (p < 0.05), with lower values for SleeperOne® device. Pain resulted significantly influenced by the type of dentition (p < 0.05), with higher scores for deciduous one. Moreover, perceived pain decreased with the increase of the age of patients (p < 0.05). At last, bitterness perception scores resulted to be higher for primary first molars (p < 0.05). SleeperOne® device seems to be a valid support for the reduction of pain related to anesthetic injection, especially in children. Further studies should evaluate CCLADs' uses combined with lidocaine preanesthetic as well as with conscious sedation through nitrous oxide in order to determine possible synergistic effects between these procedures.

Comparison between fiber-reinforced polymers and stainless steel orthodontic retainers.

OBJECTIVE: The aim of this study was to examine the properties of fiber-reinforced composite and stainless steel twisted retainers for orthodontic retention. METHODS: Three different span lengths (5.0, 8.0, and 14.0 mm) of fiber-reinforced composite were investigated. The three fiber-reinforced composite retainer groups were subdivided according to the storage condition (dry and wet), resulting in a total of six groups. Each stainless steel and fiber-reinforced composite group was comprised of six specimens. The three-point bending flexural test was conducted using a universal testing machine. ANOVA was used to assess differences in the maximum load and maximum stress according to the span length, material, and storage condition. Post-hoc comparisons were performed if necessary. RESULTS: The maximum stress and maximum load were significantly (p < 0.001) associated with the span length, material, and storage condition. The significant interaction between the material and span length (p < 0.001) indicated the differential effects of the material for each span length on the maximum stress and maximum load, with the difference between materials being the highest for the maximum span length. CONCLUSIONS: Our findings suggest that fiber-reinforced composite retainers may be an effective alternative for orthodontic retention in patients with esthetic concerns or allergy to conventional stainless steel wires.

Reliability and efficacy of palifermin in prevention and management of oral mucositis in patients with acute lymphoblastic leukemia: a randomized, double-blind controlled clinical trial.

BACKGROUND: Myeloablative and hematopoietic stem cells transplantation therapy (HSCT) often acts as side-effect to oral mucositis (OM) with no effective treatment. This randomized-controlled trial analyzed the efficacy of palifermin, administered as a dose during HSCT therapy, as primary prophylaxis on pediatric patients with acute lymphoblastic leukemia (ALL). METHODS: In this study forty-six patients (9-15 years) with B-cell acute lymphoblastic leukemia (B-ALL) were analyzed. The patients underwent allogenic HSCT conditioned by myeloablative regimen. Subsequently to randomization, patients in the palifermin group were assigned to receive palifermin, 60 mg/kg, intravenously as a single dose 3 days before and after transplant conditioning regimen cycle. The patients in the Control group received only a placebo treatment. Maximum severity of OM, incidence and duration of ulcerative OM, incidence and duration of severe OM limitations were evaluated. RESULTS: A statistically significant reduction in the incidence of OM up to grade 3 in the palifermin group compared to the control group was discovered. There was also a reduction, confirmed at 60 days, in the degree of severity of mucositis in the palifermin group, with an average of 1.54 grade in the palifermin group, and of 2.16 in the Control group and in the use of opioid analgesics. CONCLUSIONS: This study indicates that a single dose of palifermin used as primary prophylaxis during HSTC therapy can prevent severe OM in pediatric patients with ALL and used as secondary prophylaxis can prevent the recurrence of severe OM in high-risk patients with previous mucosal injury and improves the quality of life in pediatric patients with ALL.